Mitochondria have long been correlated with age-related disorders. When mitochondria reach a certain point in their “lives” they undergo a morphological change such that they transform from round and small to elongated and big. This change seems to result in loss of function, which makes sense since we know structure denotes function. Damaged mitochondria are usually degraded via a type of autophagy known as mitophagy which is specific for degradation of dysfunctional mitochondria. However, these elongated mitochondria are difficult to remove from the cell, because of their size and shape, so they tend to accumulate within the cell. This accumulation leads to cell toxicity and has been correlatively linked to age-related disorders.
Researchers at UCLA have discovered how to induce anti-aging characteristics (via promotion of healthier mitochondria) by increasing the levels of a protein that helps reduce the accumulation of dysfunctional mitochondria in cells (see image below). Typically, levels of this protein decrease with age and lead to the undesired changes in size and shape previously mentioned. Female flies lived 20% longer with this protein induction and male flies lived 12% longer than their counterparts that composed the control group. Control group flies were unable to remove damaged mitochondria efficiently after a certain age.
Here the hope is to develop drug therapies that can mimic the actions of this protein and induce similar results (delaying onset of disorders and mortality) in humans.
If we can accomplish this and live longer, should we? Why or why not?
Maleficence – we do not know what kind of side effects could result from this type of anti-aging therapies, either to the individual or our entire society. If the potential harms could outweigh the potential benefits then this is not a road we should venture onto, which leads into justice. Who will be able to obtain access to these potential anti-aging and longevity-increasing therapies, and will this be fair to all? Typically, low SES populations will not be able to access these therapies since they will be expensive and most forms of public insurance will not cover this type of treatment.
Imagine an individual who will be the next: Albert Einstein or Barbara McClintock or Jonas Salk or Rosalind Franklin or Rosa Parks or Frida Kahlo or Amelia Earhart or Mahatma Ghandi; in other words, someone that makes accomplishments that better humankind.
This individual is unable to afford this treatment but will hopefully continue to be an outstanding contributing member of society if they had more time to do so by living longer. Society might deem this individual worthy of receiving the treatment for free (if they agreed to receiving it) or at a significantly reduced cost. However, would this opportunity be extended to another individual (same sex, age, and SES) who was a single-parent raising 3 young children who was also experiencing clear symptoms of early-onset Parkinson’s Disease?
Sources:
Rana, A., Oliveira, M.P., Khamoui, A.V., et al. Promoting Drp1-mediated mitochondrial fission in midlife prolongs healthy lifespan of Drosophila melanogaster. Nature Comm 8:448, 1-14 (2017). DOI: 10.1038/s41467-017-00525-4